This past year, the august Global Think-tank on Steatotic Liver Disease developed the People-First Liver Charter (https://lnkd.in/gkbxQfc9) with a powerful shared vision: a universal approach that places people living with liver conditions at the very center of care, policy, and research.
Here’s a summary of the article “The People‑First Liver Charter” published in Nature Medicine“.
Purpose & Scope
The article presents a “people-first” framework for liver health, arguing that how we talk about, manage and govern liver conditions needs to shift away from purely a disease-centred model to one that centers the people living with liver disease. it emphasises that stigma, language, equity and integrated care must be addressed.
Key Themes
- Language & framing: The authors stress that terminology matters — for example, saying “people living with liver disease” rather than “liver disease patients” helps reduce stigma and fosters dignity.
- Holistic and integrated care: The Charter calls for care models that address not only the liver disease itself but also comorbidities, social determinants, behavioural health, prevention and long-term wellbeing.
- Equity & access: A major focus is on ensuring that all populations have access to prevention, diagnosis, treatment and support for liver conditions, especially groups historically underserved or subject to discrimination.
- Involvement & empowerment of people with lived experience: The document underscores that individuals with liver disease should be included in policy-making, research design, care planning and system-design decisions.
- Accountability & governance: It also promotes system-level accountability (governments, payers, health systems) to adopt people-first liver health strategies and measure outcomes accordingly.
Practice & Policy Implications
For clinics, researchers, policy-makers and industry, the Charter sets out implications such as:
- embedding people-first language and perspectives in all clinical, research and educational materials
- redesigning service delivery (including telehealth, multidisciplinary care) to centre on patients’ needs, preferences and context
- monitoring equity metrics in liver disease (who is being reached, who is left behind)
- building partnerships with patient-led organisations and ensuring meaningful patient engagement
- aligning innovation and research priorities with the lived-experience of those with liver disease.
Why It Matters
Given the global burden of liver disease (including viral hepatitis, metabolic-associated steatotic liver disease (MASLD), alcohol-related liver disease), this Charter is timely. It offers a blueprint for transforming how the field addresses not just the biomedical aspects of liver disease but the human and systemic dimensions too. This aligns strongly with person‐centered care, presumably telehealth innovation and partnerships across care settings.